• 1
    Fock KM, Katelaris P, Sugano K et al. Second Asia–Pacific Consensus Guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2009; 24: 1587600.
  • 2
    Asaka M, Kato M, Takahashi S et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 120.
  • 3
    Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 77281.
  • 4
    Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 2007; 102: 180825.
    Direct Link:
  • 5
    Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin. Gastroenterol. Hepatol. 2009; 7: 1458.
  • 6
    Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment. Pharmacol. Ther. 2007; 26: 34357.
  • 7
    McMahon BJ, Hennessy TW, Bensler JM et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann. Intern. Med. 2003; 139: 4639.
  • 8
    Hoshiya S, Watanabe K, Tokunaga K et al. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J. Gastroenterol. 2000; 35: 1014.
  • 9
    Romano M, Iovene MR, Russo MI et al. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J. Clin. Pathol. 2008; 61: 111215.
  • 10
    Furuta T, Shirai N, Takashima M et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 2001; 69: 15868.
  • 11
    Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am. J. Gastroenterol. 2006; 101: 146775.
    Direct Link:
  • 12
    Gené E, Calvet X, Azagra R, Gisbert JP. Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment. Pharmacol. Ther. 2003; 18: 5434.
  • 13
    Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand. J. Gastroenterol. 2001; 36: 690700.
  • 14
    Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment. Pharmacol. Ther. 2011; 34: 60417.
  • 15
    Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am. J. Gastroenterol. 2006; 101: 48896.
    Direct Link:
  • 16
    Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann. Intern. Med. 2008; 148: 92331.
  • 17
    Greenberg ER, Anderson GL, Morgan DR et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378: 50714.
  • 18
    Hsu PI, Wu DC, Wu JY, Graham DY. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter 2011; 16: 14652.
  • 19
    Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16: 13945.
  • 20
    Miehlke S, Kirsch C, Schneider-Brachert W et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003; 8: 31019.
  • 21
    Furuta T, Sugimoto M, Kodaira C et al. The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori. Hepatogastroenterology 2010; 57: 1349.
  • 22
    Kim SY, Jung SW, Kim JH et al. Effectiveness of three-times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea. Br. J. Clin. Pharmacol. 2011 DOI: 10.1111/j.13652125.2011.04048X.
  • 23
    Attumi TA, Graham DY. Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: A pilot study. J. Gastroenterol. Hepatol. 2012; 27: 5961.
  • 24
    Leach AJ, Morris PS, Mathews JD; The Chronic Otitis Media Intervention Trial-One (COMIT1) group. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatr. 2008; 8: 23.
  • 25
    Meropol SB, Chan KA, Chen Z et al. Adverse events associated with prolonged antibiotic use. Pharmacoepidemiol. Drug Saf. 2008; 17: 52332.
  • 26
    Chung JW, Lee JH, Jung HY et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011; 16: 28994.
  • 27
    Tanimura H, Kawano S, Kubo M et al. Does Helicobacter pylori eradication depend on the period of amoxicillin treatment? A retrospective study. J. Gastroenterol. 1998; 33: 236.
  • 28
    Furuta T, Sagehashi Y, Shirai N et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin. Gastroenterol. Hepatol. 2005; 3: 56473.